NCT00249106已完成1 期
Randomized, Placebo-Controlled, Dose-Escalating, Double-Blinded Phase 1 Safety and Immunogenicity Study of Clade C DNA Vaccine ADVAX e/g + ADVAX p/N-t (ADVAX) Administered Intramuscularly to HIV-Uninfected, Healthy Volunteers.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 3
- 主要终点
- Safety of ADVAX
研究概览
简要总结
The purpose of this study is to determine the safety and immune response to a investigational DNA Plasmid HIV vaccine, ADVAX e/g + ADVAX p/n-t (ADVAX), at three different dosage levels, in adults who are not infected with HIV.
详细描述
This is a dose escalation trial. Study site staff and volunteers will be blinded, blinding will not apply to the assignment of dose levels (low, middle or high).
Volunteers will be screened up to 42 days before vaccination and will be followed for 18 months after the first vaccination.
15 volunteers will be randomized in a 4:1 ratio of active vaccine to placebo. Safety and tolerability of the ADVAX e/g + ADVAX p/n-t investigational product will be evaluated at least 14 days after the tenth volunteer in the lower dosage group receives the second injection before proceeding to the nextdosage group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, adult males and females;
- •Age at least 18 years on the day of screening and no greater than 60 years on the day of the first vaccination;
- •Available for follow up for the planned duration of the study (screening plus 18 months);
- •In the opinion of the principal investigator or designee, has understood the information provided. Written informed consent needs to be given before any study-related procedures are performed;
- •Willing to undergo HIV testing and counseling, and receive HIV test results;
- •If sexually active female, using an effective method of contraception from screening until at least 4 months after last vaccination, and willing to undergo urine pregnancy test.
- •If sexually active male, willing to use an effective method of contraception from screening until 4 months after the last vaccination.
排除标准
- •Clinically relevant abnormality on history or examination including history of immunodeficiency or use of systemic corticosteroids, immunosuppressive, antiviral, anticancer, or other medications considered significant by the designated trial physician in last 6 months;
- •Any acute or chronic medical condition requiring care of a physician (e.g.,, diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that, in the opinion of the investigator, would preclude participation;
- •Any of the following abnormal laboratory parameters that are moderate, severe, or very severe: haematology (hemoglobin, absolute neutrophil count, absolute lymphocyte count, absolute CD4/CD8 count, platelets); urinalysis, biochemistries (total bilirubin, creatinine, AST, ALT). Volunteers with mild laboratory abnormalities that are judged by the principal investigator or designee to be not clinically significant may be enrolled.
- •Reported high- risk behaviour for HIV infection, defined as:
- •Had unprotected vaginal or anal sex with a known HIV infected person or a casual partner (i.e., no continuing established relationship) within 6 months before vaccination
- •Engaged in sex work for money or drugs within 6 months before vaccination
- •Used injection drugs (illicit), or Acquired an STD within 6 months before vaccination ;
- •If female, pregnant or planning a pregnancy within 4 months after last vaccination or lactating;
- •Receipt of blood transfusion or blood products 6 months prior to vaccination;
- •Receipt of a live attenuated vaccine (other than influenza) within 30 days or other vaccine within 14 days of vaccination;
- •Participation in another clinical trial of an investigational product currently or within past 12 weeks or expected participation during this study;
- •Receipt of another experimental HIV vaccine at any time;
- •Infected with HIV-1 or HIV-2 as indicated by ELISA and/or RT-PCR;
- •History of severe local or systemic reaction to vaccination or history of severe allergic reactions;
- •Confirmed diagnosis of hepatitis B (surface antigen, HbsAg); hepatitis C (HCV antibodies) or active syphillis;
- •History of grand-mal epilepsy, or currently taking anti-epileptics;
- •In the opinion of the investigator, unlikely to comply with protocol.
结局指标
主要结局
Safety of ADVAX
时间窗: 18 months
dose escalation study
次要结局
- Immunogenicity of ADVAX(18 months)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative AdultsHIV InfectionsNCT00574600National Institute of Allergy and Infectious Diseases (NIAID)48
已完成
2 期
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA VaccineHerpes GenitalisNCT02837575Vical261
已完成
1 期
The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy VolunteersSARS-CoV2 COVID-19NCT04742842University of Sydney68
已完成
1 期
Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy AdultsHIV InfectionsNCT00472719National Institute of Allergy and Infectious Diseases (NIAID)17
已完成
1 期
Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy AdultsHIV InfectionsNCT00528489National Institute of Allergy and Infectious Diseases (NIAID)120